NCT00953615View on ClinicalTrials.gov

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Primary Sclerosing Cholangitis

Interventions

DRUG

Thalidomide

Titrate to 400 mg daily for 6 months

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Mayo Clinic

OTHER